Use of malondialdehyde (MDA) as a screening tool for vestibulopathy inType2 diabetes mellitus

Abstract

Introduction and Aim:Diabetes mellitus, especially type II DM is one among the most prevalent metabolic diseases in the global scale. One of the commonest complications of diabetes mellitus is vestibulopathy affecting the inner ear. Malondialdehyde (MDA) obtained from lipid peroxidation of poly unsaturated fatty acids (PUFA) is an important compound that generally serves as one of the key markers for oxidative stress. The aim of the study is to prove the significance of MDA in Vestibulopathy in Type-2 i.e.,non-insulin dependent diabetes mellitus.
 
 Methodology: A cross-sectional study of 100 diabetic patients of age group between 35 years and 50 years were tested for vestibular function by electronystagmography(Commonly used test to determine and evaluate vestibular system). Based on the biothermal caloric stimulation the Clausen butterfly chart was generated and thus the code is ascertained. Serum levels of Malon-di-aldehyde were assayed by TBARS method (Thiobarbituric acid Reactive substances).
 
 Results: The study proved, that there was a 4 times increased risk of developing vestibulopathy with increasing duration of diabetes. It also proved that there was an increased risk of developing vestibulopathy in diabetic patients, having MDA > 2?mol/L.
 
 Conclusion: Thereby the study confirmed the clinical significance of periodic screening of MDA levels, in diabetic patients, particularly those with uncontrolled/poor glycemic control & with longer duration of diabetes. Estimation of their serum MDAlevels and vestibular function by the electronystagmography test, is advised in order to prevent the occurrence of diabetic vestibulopathy at the earliest and also to prevent the worsening of any such, other complications associated with the disease.